Resources Repository
-
ArticlePublication 2017Predicting Carer Health Effects for Use in Economic Evaluation
Illnesses and interventions can affect the health status of family carers in addition to patients. …
Illnesses and interventions can affect the health status of family carers in addition to patients. However economic evaluation studies rarely incorporate data on health status of carers. In order to investigate whether changes in carer health status could be ‘predicted’ from the health data of those they provide care to, as a means of incorporating carer outcomes in economic evaluation, the authors used regression models to analyse changes in carers’ health status. They derive predictive algorithms based on…
Cost-Effectiveness Analysis | Europe | North America | Infectious Diseases | Preferences/Values | Health Outcomes | Health/Medicine -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Cost-Effectiveness Analysis | Europe | North America | Infectious Diseases | Preferences/Values | Costing Methods | Health Outcomes | Mathematical Models | Clinical Care | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Cost-Effectiveness Analysis | Calibration/Validation | North America | Infectious Diseases | Dynamic Transmission | Microsimulation | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Cost-Effectiveness Analysis | Calibration/Validation | North America | Infectious Diseases | Dynamic Transmission | Microsimulation | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Cost-Effectiveness Analysis | Europe | North America | Infectious Diseases | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | State-Transition | Decision Analysis | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Test Performance | Mathematical Models | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Early HPV Natural History Transitions
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on …
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on accurate transition risks for human papillomavirus (HPV) infection, persistence (or absence of HPV clearance), progression to precancerous lesions, and invasion. To inform the refinement of such models, we compared the early natural history of HPV types using prospective data from immunocompetent women in the Guanacaste Natural History Study, the ASCUS-LSIL Triage Study, and the Costa Rica HPV Vaccine Trial. We…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Mathematical Models | Microsimulation | Latin America & Caribbean -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Evidence Synthesis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine